- Report
- October 2024
- 183 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- October 2024
- 186 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- March 2025
- 373 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Report
- March 2025
- 179 Pages
Global
From €5201EUR$5,450USD£4,358GBP
- Report
- March 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- August 2024
- 147 Pages
Global
From €2862EUR$2,999USD£2,398GBP
- Report
- May 2024
- 134 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 129 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3579EUR$3,750USD£2,999GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1193EUR$1,250USD£1,000GBP
- Report
- November 2021
- 295 Pages
Global
From €2625EUR$2,750USD£2,199GBP
€5249EUR$5,500USD£4,398GBP
- Report
- April 2023
- 147 Pages
Global
From €4723EUR$4,949USD£3,957GBP
- Report
- January 2024
- 200 Pages
Global
From €3961EUR$4,150USD£3,318GBP
- Report
- April 2023
- 120 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- April 2022
- 210 Pages
Global
From €3298EUR$3,456USD£2,764GBP

Caspofungin is an antifungal drug used to treat a variety of fungal infections, including those caused by Candida species. It is a member of the echinocandin class of antifungal drugs, which are used to treat serious fungal infections in immunocompromised patients. Caspofungin is typically used in combination with other antifungal drugs, such as amphotericin B or fluconazole, to treat infections that are resistant to other antifungal agents. It is also used to treat infections caused by Aspergillus species, which are often difficult to treat.
Caspofungin is an important drug in the treatment of infectious diseases, as it is effective against a wide range of fungal infections. It is also well tolerated, with few side effects. As such, it is an important part of the infectious diseases drugs market.
Companies in the caspofungin market include Merck & Co., Pfizer, Astellas Pharma, and Bristol-Myers Squibb. Show Less Read more